Literature DB >> 6175409

ABVD chemotherapy in the treatment of Hodgkin's disease.

G Bonadonna, A Santoro.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175409     DOI: 10.1016/s0305-7372(82)80003-0

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  14 in total

1.  Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report.

Authors:  Karen S Fernández; Cindy L Schwartz; Lu Chen; Louis S Constine; Allen Chauvenet; Pedro A de Alarcón
Journal:  Pediatr Blood Cancer       Date:  2017-06-14       Impact factor: 3.167

Review 2.  Current approaches to the treatment of advanced-stage Hodgkin's disease.

Authors:  J J Rusthoven
Journal:  CMAJ       Date:  1986-09-01       Impact factor: 8.262

Review 3.  Early-stage Hodgkin's disease: current approaches to treatment.

Authors:  J J Rusthoven; R MacKenzie
Journal:  Can Med Assoc J       Date:  1985-08-01       Impact factor: 8.262

Review 4.  Current management of Hodgkin's disease.

Authors:  B C Behrens; R C Young; V T DeVita
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 5.  Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.

Authors:  Melissa M Hudson; Joseph P Neglia; William G Woods; John T Sandlund; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Daniel M Green
Journal:  Pediatr Blood Cancer       Date:  2011-10-28       Impact factor: 3.167

Review 6.  [Pathogenesis and therapy of Hodgkin lymphoma].

Authors:  H Tesch; H Bohlen; J Wolf; A Engert
Journal:  Med Klin (Munich)       Date:  1998-02-15

Review 7.  Management of Hodgkins Lymphoma: ICMR Consensus Document.

Authors:  Venkatraman Radhakrishnan; Gauri Kapoor; Brijesh Arora; Deepak Bansal; Tushar Vora; Maya Prasad; Girish Chinnaswamy; Siddharth Laskar; Sandeep Agarwala; Tanvir Kaur; G K Rath; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2017-03-30       Impact factor: 1.967

8.  Phase II study of NK313 in malignant lymphomas: an NK313 Malignant Lymphoma Study Group trial.

Authors:  T Yoshida; M Ogawa; K Ota; Y Yoshida; A Wakui; M Oguro; Y Ariyoshi; M Hirano; I Kimura; T Matsuda
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea.

Authors:  June-Won Cheong; Soo Young Park; Jae Kyung Roh; Chang Ok Suh; Jee Sook Hahn
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

Review 10.  Drug resistance and cancer chemotherapy strategy in breast cancer.

Authors:  J H Goldie
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.